GREGORY BROWN: Open Payments
NPI 1821058181 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$117,397 in 202 payments from 10 companies in 2025. Trend: 2023 $95,084 · 2024 $80,693 · 2025 $117,397
Speaker / faculty: $73,734Honoraria: $24,250Travel & lodging: $7,703Consulting: $6,888Food & beverage: $4,800Education: $22
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 56 | $41,844 |
| Supernus Pharmaceuticals, Inc. | 45 | $28,365 |
| Neurocrine BioSciences, Inc. | 31 | $26,306 |
| ABBVIE INC. | 32 | $19,690 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $394 |
| Alkermes, Inc. | 14 | $270 |
| Axsome Therapeutics, Inc. | 3 | $257 |
| E.R. Squibb & Sons, L.L.C. | 5 | $185 |
| Lundbeck LLC | 3 | $63 |
| Corium, LLC | 1 | $23 |
Products named: REXULTI, Qelbree, INGREZZA, VRAYLAR, CAPLYTA, ARISTADA, Auvelity, COBENFY.
Industry payments across LA — which companies pay providers there.
